| 2022-08-11 9:19:56 am |
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript |
SeekingAlpha |
| Aug-11-22 08:00AM |
Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results |
GlobeNewswire |
| Aug-04-22 04:05PM |
Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022 |
GlobeNewswire |
| Aug-04-22 08:00AM |
Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results |
GlobeNewswire |
| Jul-29-22 04:05PM |
Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock |
GlobeNewswire |
| Jul-15-22 08:00AM |
Synthetic Biologics Announces Reverse Stock Split |
GlobeNewswire |
| May-16-22 08:00AM |
Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results |
GlobeNewswire |
| May-10-22 12:24PM |
Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers |
Benzinga |
| May-10-22 08:00AM |
Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial |
GlobeNewswire |
| May-09-22 08:00AM |
Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results |
GlobeNewswire |
| May-05-22 08:00AM |
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline |
GlobeNewswire |
| May-04-22 08:00AM |
Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) |
GlobeNewswire |
| Mar-29-22 09:44AM |
Synthetic Biologics' VCN-01 Shows Favorable Safety Profile, Clinical Activity In Early-Stage Cancer Study |
Benzinga |
| Mar-28-22 04:05PM |
Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors |
GlobeNewswire |
| Mar-23-22 08:00AM |
Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation |
GlobeNewswire |
| Mar-22-22 04:05PM |
Synthetic Biologics to Participate in the Maxim 2022 Virtual Growth Conference |
GlobeNewswire |
| Mar-16-22 04:05PM |
Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results |
GlobeNewswire |
| Mar-11-22 08:00AM |
Synthetic Biologics Completes Acquisition of VCN Biosciences |
GlobeNewswire |
| Mar-10-22 04:30PM |
Synthetic Biologics to Host Conference Call and Webcast to Discuss 2021 Year End Operational Highlights and Financial Results |
GlobeNewswire |
| Feb-09-22 07:15AM |
Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference |
PR Newswire |
| Feb-08-22 07:15AM |
Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA |
PR Newswire |
| Jan-26-22 04:05PM |
Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 |
PR Newswire |
| Dec-14-21 07:00AM |
Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors |
PR Newswire |
| Nov-03-21 04:10PM |
Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET |
PR Newswire |
| Oct-26-21 07:00AM |
Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 |
PR Newswire |
| Oct-21-21 07:00AM |
Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase |
PR Newswire |
| Oct-06-21 04:30PM |
Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum |
PR Newswire |
| Sep-21-21 04:30PM |
Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum |
PR Newswire |
| Sep-10-21 12:19PM |
7 Biotech Stocks to Buy That Have Millionaire-Maker Potential |
InvestorPlace |
| Aug-05-21 04:10PM |
Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET |
PR Newswire |
| Aug-03-21 07:00AM |
Synthetic Biologics Expands Option for an Exclusive License Agreement with Massachusetts General Hospital |
PR Newswire |
| Jul-28-21 07:00AM |
Synthetic Biologics to Report 2021 Second Quarter Operational Highlights and Financial Results on August 5, 2021 |
PR Newswire |
| Jun-29-21 07:00AM |
Synthetic Biologics Provides Update on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Single-Ascending Dose Clinical Trial |
PR Newswire |
| Jun-14-21 03:35PM |
Hedge Funds Are Nibbling On Synthetic Biologics Inc (SYN) |
Insider Monkey |
| May-26-21 07:00AM |
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards |
PR Newswire |
| May-05-21 04:10PM |
Synthetic Biologics Reports 2021 First Quarter Operational Highlights and Financial Results |
PR Newswire |
| May-05-21 02:30PM |
Synthetic Biologics, Inc. to Host Earnings Call |
ACCESSWIRE |
| Apr-28-21 07:00AM |
Synthetic Biologics to Report 2021 First Quarter Operational Highlights and Financial Results on May 5, 2021 |
PR Newswire |
| Apr-14-21 07:00AM |
Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients |
PR Newswire |
| Apr-01-21 07:00AM |
Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase |
PR Newswire |
| Mar-04-21 04:10PM |
Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results |
PR Newswire |
| Mar-04-21 02:30PM |
Synthetic Biologics, Inc. to Host Earnings Call |
ACCESSWIRE |
| Feb-04-21 05:38AM |
How Many Synthetic Biologics, Inc. (NYSEMKT:SYN) Shares Did Insiders Buy, In The Last Year? |
Simply Wall St. |
| Dec-22-20 07:00AM |
Synthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol |
PR Newswire |
| Nov-24-20 07:00AM |
Synthetic Biologics Announces Extension of Compliance Plan Period by NYSE American |
PR Newswire |
| Nov-16-20 07:00AM |
Synthetic Biologics Engages A.G.P./Alliance Global Partners as Advisor to Assist in Evaluating Strategic Options |
PR Newswire |
| Nov-12-20 07:00AM |
Synthetic Biologics Welcomes Senior Biotech Executive John Monahan, PhD, to Board of Directors |
PR Newswire |
| Nov-10-20 04:15PM |
Synthetic Biologics Reports 2020 Third Quarter Operational Highlights and Financial Results |
PR Newswire |
| Nov-10-20 02:45PM |
Synthetic Biologics, Inc. to Host Earnings Call |
ACCESSWIRE |
| Nov-03-20 04:30PM |
Synthetic Biologics to Report 2020 Third Quarter Operational Highlights and Financial Results on November 10, 2020 |
PR Newswire |
| Oct-02-20 07:00AM |
Synthetic Biologics Provides Update on Investigator-Sponsored Phase 2b Clinical Study of SYN-010 in IBS-C Patients |
PR Newswire |
| Jun-30-20 07:00AM |
Synthetic Biologics Announces Submission of IND Application to U.S. FDA for SYN-020 Intestinal Alkaline Phosphatase |
PR Newswire |
| Jun-15-20 11:41AM |
Edited Transcript of SYN.A earnings conference call or presentation 5-May-20 8:30pm GMT |
Thomson Reuters StreetEvents |
| May-27-20 07:00AM |
Synthetic Biologics Enters into Exclusive Option to License Intellectual Property for Use of SYN-020 to Treat and Prevent Age-Related Metabolic and Inflammatory Diseases |
PR Newswire |
| May-13-20 12:20PM |
Sýn hf.: Q1 2020 affected by the COVID-19 pandemic |
GlobeNewswire |
| May-06-20 09:55AM |
How Synthetic Biologics, Inc. (NYSEMKT:SYN) Can Impact Your Portfolio Volatility |
Simply Wall St. |
| May-05-20 04:15PM |
Synthetic Biologics Reports 2020 First Quarter Operational Highlights and Financial Results |
PR Newswire |
| Apr-28-20 04:30PM |
Synthetic Biologics to Report 2020 First Quarter Operational Highlights and Financial Results on May 5, 2020 |
PR Newswire |
| Mar-16-20 03:41PM |
First human trial for coronavirus vaccine begins today: AP |
Yahoo Finance Video |
| Feb-26-20 12:29PM |
Results in line with outlook |
GlobeNewswire |
| Feb-23-20 02:26PM |
Edited Transcript of SYN earnings conference call or presentation 20-Feb-20 9:30pm GMT |
Thomson Reuters StreetEvents |
| Feb-20-20 04:15PM |
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results |
PR Newswire |
| Feb-07-20 04:30PM |
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American |
PR Newswire |
| Feb-06-20 01:53PM |
We Think Synthetic Biologics (NYSEMKT:SYN) Needs To Drive Business Growth Carefully |
Simply Wall St. |
| Jan-07-20 07:00AM |
Synthetic Biologics Receives FDA Guidance at Type C Meeting for SYN-004 (ribaxamase) Phase 1b/2a Clinical Trial in Allogeneic HCT Recipients |
PR Newswire |
| Dec-30-19 05:54AM |
Sýn hf.: Financial calendar 2020 |
GlobeNewswire |
| Dec-24-19 07:29AM |
Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements |
GlobeNewswire |
| Nov-30-19 09:39AM |
Is Synthetic Biologics Inc (SYN) Going To Burn These Hedge Funds ? |
Insider Monkey |
| Nov-27-19 04:30PM |
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan |
PR Newswire |
| Nov-21-19 12:21AM |
Edited Transcript of SYN earnings conference call or presentation 4-Nov-19 9:30pm GMT |
Thomson Reuters StreetEvents |
| Nov-14-19 11:23AM |
Sýn hf.: Landsdowne Partners International Limited - Major shareholder announcements |
GlobeNewswire |
| Nov-06-19 12:02PM |
Sýn hf.: Best operating profit of the year |
GlobeNewswire |
| Nov-04-19 04:10PM |
Synthetic Biologics Reports Third Quarter 2019 Operational Highlights and Financial Results |
PR Newswire |
| Oct-28-19 04:30PM |
Synthetic Biologics to Report 2019 Third Quarter Operational Highlights and Financial Results on November 4, 2019 |
PR Newswire |
| Sep-26-19 07:00AM |
Synthetic Biologics Strengthens U.S. Patent Coverage of SYN-010, Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) |
PR Newswire |
| Sep-06-19 11:24AM |
Does The Synthetic Biologics, Inc. (NYSEMKT:SYN) Share Price Tend To Follow The Market? |
Simply Wall St. |
| Sep-01-19 10:50PM |
Edited Transcript of SYN earnings conference call or presentation 8-Aug-19 8:30pm GMT |
Thomson Reuters StreetEvents |
| Aug-28-19 01:12PM |
Sýn hf.: Financial results below expectations but positive outlook |
GlobeNewswire |
| Aug-20-19 09:46AM |
Sýn hf.: Change in guidance |
GlobeNewswire |
| Aug-08-19 04:15PM |
Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Results |
PR Newswire |
| Aug-01-19 07:00AM |
Synthetic Biologics to Report 2019 Second Quarter Operational Highlights and Financial Results on August 8, 2019 |
PR Newswire |
| Jul-01-19 07:00AM |
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards |
PR Newswire |
| May-27-19 03:14PM |
Those Who Purchased Synthetic Biologics (NYSEMKT:SYN) Shares Three Years Ago Have A 99% Loss To Show For It |
Simply Wall St. |
| May-24-19 10:25AM |
Sýn hf.: Notification of related party trading |
GlobeNewswire |
| May-22-19 12:55PM |
Edited Transcript of SYN earnings conference call or presentation 8-May-19 8:30pm GMT |
Thomson Reuters StreetEvents |
| May-08-19 06:02PM |
Synthetic Biologics: 1Q Earnings Snapshot |
Associated Press |
| May-08-19 04:10PM |
Synthetic Biologics Reports First Quarter 2019 Operational Highlights and Financial Results |
PR Newswire |
| Apr-30-19 04:30PM |
Synthetic Biologics to Report 2019 First Quarter Operational Highlights and Financial Results on May 8, 2019 |
PR Newswire |
| Apr-20-19 03:38AM |
Edited Transcript of SYN earnings conference call or presentation 27-Feb-19 9:30pm GMT |
Thomson Reuters StreetEvents |
| Feb-27-19 04:10PM |
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results |
PR Newswire |
| Feb-27-19 03:05PM |
Sýn hf. : Q4 Investors presentation |
GlobeNewswire |
| Feb-27-19 02:55PM |
Sýn hf. : Changes in management of Sýn hf. |
GlobeNewswire |
| Feb-27-19 02:53PM |
Sýn hf. : Merged company completes its first full year under challenging market conditions |
GlobeNewswire |
| Feb-26-19 10:38AM |
Sýn hf. : Sýn finalizes the merger of Hey P/F with Nema P/F |
GlobeNewswire |
| Feb-19-19 04:30PM |
Synthetic Biologics to Report 2018 Year End Operational Highlights and Financial Results on February 27, 2019 |
PR Newswire |
| Jan-03-19 07:00AM |
Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored |
PR Newswire |
| Dec-18-18 10:38AM |
Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT |
Thomson Reuters StreetEvents |
| Dec-04-18 12:00PM |
Orchestra BioMed Appoints C. Evan Ballantyne as Chief Financial Officer |
GlobeNewswire |
| Nov-27-18 08:20AM |
Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland New Horizons, Emerging Trends, and Upcoming Developments |
GlobeNewswire |
| Nov-22-18 09:10AM |
New Trends in Healthcare Push Stocks Higher: 5 Picks |
Zacks |
| Nov-21-18 09:25AM |
New Healthcare Trends Could Push Sector Stocks Higher |
ACCESSWIRE |